Tel Aviv, April 6, 2015 – Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Anat Cohen-Dayag, PhD, President and Chief Executive Officer, Compugen, will present aspects of the Company’s immune checkpoint programs at two oncology conferences in Boston this month.
Dr. Cohen-Dayag will deliver a presentation at the Jefferies Immuno-Oncology Summit, to be held on April 15, 2015. In her talk, Dr. Cohen-Dayag will discuss Compugen’s broadly applicable predictive discovery approach with emphasis on its first focused discovery program, which resulted in the identification of multiple novel immune checkpoint candidates. Dr. Cohen-Dayag will also present experimental data for selected Compugen-discovered novel immune checkpoints now being advanced by the Company as target candidates for cancer immunotherapy.
In addition, Dr. Cohen-Dayag will participate in a panel discussion titled Focus on Immunotherapy: The Future at the Cancer Advance Boston conference at Harvard Medical School, Harvard University on April 14, 2015.
About Compugen’s Programs for Cancer Immunotherapy
Compugen’s cancer immunotherapy programs are based on eleven novel B7/CD28-like immune checkpoint candidates and four novel immunomodulators distinct from the B7/CD28-like proteins, all of which were initially predicted in silico by Compugen. Immune checkpoints, including inhibitory receptors and ligands, are immunomodulatory proteins which are crucial for the maintenance of self-tolerance (the prevention of autoimmunity) and for the protection of tissues from damage during an immune response. Immune checkpoints are “hijacked” by tumors to block the ability of the immune system to destroy the tumor cells. Therapeutic blockade of immune checkpoints can boost anti-tumor immunity, enabling the patient’s immune system to recognize and attack the tumor cells, and mount durable anti-tumor responses leading to tumor destruction.
Compugen is a leading predictive drug discovery company focused on monoclonal antibodies and therapeutic proteins to address important unmet needs in the fields of oncology and immunology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of novel drug target candidates, which are then advanced in its Pipeline Program. The discovery and development of monoclonal antibody therapeutic candidates against selected Compugen-discovered novel target candidates is performed by Compugen’s wholly-owned U.S. subsidiary located in South San Francisco. The Company’s business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. For additional information, please visit Compugen’s corporate website at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks include: that Compugen’s business model is substantially dependent on entering into collaboration agreements with third parties and may not be successful in generating revenues, and that the development and commercialization of therapeutic products includes many inherent risks, including failure to receive regulatory approval. These and other factors are more fully discussed in the “Risk Factors” section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission as well as other documents that may be subsequently filed by Compugen from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.
Global Media Liaison